Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Regeneron Pharmaceuticals

FAST NEWS: Henlius Lung Cancer Drug Gets ‘Orphan’ Status in Europe

The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Thursday its self-developed small cell lung cancer drug Hansizhuang has been granted orphan drug status by the European Commission (EC).Looking up:…
December 16, 2022

Biocytogen Unleashes Legions of High-Tech Mice to Lure IPO Investors

The major provider of gene-edited lab rodents gets the nod for a Hong Kong listing after abandoning a plan to float shares on Shanghai’s STAR Market Key Takeaways: Gene-edited lab…
August 17, 2022

Recent Articles

December 16, 2022

FAST NEWS: Henlius Lung Cancer Drug Gets ‘Orphan’ Status in Europe

August 17, 2022

Biocytogen Unleashes Legions of High-Tech Mice to Lure IPO Investors

RELATED ARTICLES

  1. Henlius Bio
    February 6, 2025
    After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  2. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  3. December 19, 2024
    Hengrui Pharma accelerates bid for global brand status
    600276.SHG
  4. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.